Evidence map›Paper›PMID 29191058›Full record

ArticleDrug delivery2017

Nanoemulsion-based delivery system for enhanced oral bioavailability and caco-2 cell monolayers permeability of berberine hydrochloride.

Yong-Jiang Li, Xiong-Bin Hu, Xiu-Ling Lu, De-Hua Liao, Tian-Tian Tang, Jun-Yong Wu, Da-Xiong Xiang

Open access · goldAbstract read
In one paragraph

Article in Drug delivery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 54 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Research progress on pharmacological effects and bioavailability of berberine.Naunyn-Schmiedeberg's archives of pharmacology · 2024
    Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Berberine inhibits liver damage in rats with non-alcoholic fatty liver disease by regulating TLR4/MyD88/NF-κB pathway.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2020
    Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Yong-Jiang Lia Department of Pharmacy , The Second Xiangya Hospital, Central South University , Changsha , Hunan , China.
Xiong-Bin Hua Department of Pharmacy , The Second Xiangya Hospital, Central South University , Changsha , Hunan , China.
Xiu-Ling Lua Department of Pharmacy , The Second Xiangya Hospital, Central South University , Changsha , Hunan , China.
De-Hua Liaoa Department of Pharmacy , The Second Xiangya Hospital, Central South University , Changsha , Hunan , China.
Tian-Tian Tanga Department of Pharmacy , The Second Xiangya Hospital, Central South University , Changsha , Hunan , China.
Jun-Yong Wua Department of Pharmacy , The Second Xiangya Hospital, Central South University , Changsha , Hunan , China.
Da-Xiong Xianga Department of Pharmacy , The Second Xiangya Hospital, Central South University , Changsha , Hunan , China.
Second Xiangya Hospital of Central South University · CNCentral South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Berberine hydrochloride (BBH) has a variety of pharmacological activities such as antitumor, antimicrobial, anti-inflammation, and reduce irritable bowel syndrome. However, poor stability and low oral bioavailability limited its usage. Herein, an oil-in-water nanoemulsion system of BBH was developed to improve its stability and oral bioavailability. The pseudoternary phase diagrams were constructed for the determination of composition of various nanoemulsions. The nanoemulsions of BBH composed of Labrafil M 1944 CS (oil phase), RH-40 (surfactant), glycerin (co-surfactant), and water (aqueous phase). The O/W nanoemulsion of BBH showed a relative bioavailability of 440.40% compared with unencapsulated BBH and was stable in our 6-month stability study. Further, there was a significant increase in intestinal permeability of BBH as assessed by Caco-2 cell monolayers and a significant reduction in efflux of BBH by the multidrug efflux pump P-glycoprotein. This study confirmed that the nanoemulsion formulation could be used as an alternative oral formulation of BBH to improve its stability, oral bioavailability and permeability.

Indexed as

Administration, OralBerberineBiological AvailabilityCaco-2 CellsCell Line, TumorDrug Delivery SystemsEmulsionsGlyceridesHumansIntestinal AbsorptionNanoparticlesPermeabilityPolyethylene GlycolsSolubilitySurface-Active AgentsWaterBerberineEmulsionsGlyceridesLabrafil M 1944 CSPolyethylene GlycolsSurface-Active AgentsWaterBerberine hydrochloridebioavailabilityCaco-2 cellsnanoemulsiontransport

Identifiers

PMID29191058
PMCPMC8240975
OpenAlexW2775504258

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.